Kemikos

Kemikos is a biotechnology company focused on the discovery and development of next-generation covalent small molecule therapeutics. Founded by renowned scientists Benjamin Cravatt and Phil Baran from Scripps Research, the company leverages a proprietary chemoproteomics platform to map the ligandable proteome and identify novel targets for covalent modification. By combining advanced synthetic chemistry with high-throughput screening, Kemikos aims to address previously "undruggable" targets across various therapeutic areas, including oncology and immunology. The company is currently in the pre-clinical stage, building a pipeline of precision medicines. Kemikos is backed by leading life science investors, including ARCH Venture Partners, and operates primarily in stealth mode.